STOCK TITAN

OM Rule 144 Notice: 243 Shares From Vested RSUs to Be Sold on NASDAQ

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filing for Outset Medical, Inc. (OM) documents a proposed sale of 243 shares of Common Stock through Morgan Stanley Smith Barney with an aggregate market value of $3,129.84, to be sold on 08/15/2025 on NASDAQ. The shares were acquired on 08/15/2025 as settlement of vested restricted stock units and were paid as equity compensation for services. The filer also disclosed a prior sale of 252 shares on 05/15/2025 generating gross proceeds of $4,490.50. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

  • Timely compliance: Form 144 filed to disclose proposed sale under Rule 144, meeting regulatory notice requirements
  • Source of shares disclosed: Shares were acquired as settlement of vested restricted stock units, indicating equity compensation rather than open-market purchase

Negative

  • None.

Insights

TL;DR: Small, routine insider sale from vested RSUs; immaterial to company valuation but important for regulatory transparency.

The filing shows a proposed sale of 243 shares with a market value of $3,129.84 arising from settlement of vested restricted stock units and scheduled for sale the same day. Given the outstanding share count of 17,766,193, this represents an immaterial percentage of equity. The disclosure is consistent with Rule 144 notice requirements and recent insider liquidity activity; it provides transparency but likely has no material impact on firm fundamentals.

TL;DR: Filing demonstrates compliance with securities rules and confirms insider exercised compensation-related liquidity.

The notice includes the requisite representation about absence of undisclosed material information and ties the acquisition to equity compensation. The transaction is routine for executive or employee holders converting vested RSUs to shares for sale. From a governance perspective, timely and complete Form 144 disclosure is a positive compliance signal. The small absolute size reduces the governance or market-signaling concern.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for Outset Medical (OM) disclose about the proposed sale?

It discloses a proposed sale of 243 shares of Common Stock with aggregate market value of $3,129.84 to be sold on 08/15/2025 on NASDAQ.

How were the 243 shares acquired according to the filing?

The filing states the shares were acquired on 08/15/2025 as settlement of vested restricted stock units, paid as equity compensation for services.

Has the filer sold any Outset Medical (OM) shares recently?

Yes. The filing discloses a prior sale of 252 shares on 05/15/2025 with gross proceeds of $4,490.50.

Which broker is handling the proposed sale in the Form 144?

The broker listed is Morgan Stanley Smith Barney LLC located at 1 New York Plaza, 38th Floor, New York, NY.

Does the filing indicate any undisclosed material adverse information?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed, as required by the form.